Skip to main content

Table 3 AEs leading to treatment discontinuation in three or more patients

From: Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study

AE, n (%) Daclizumab 150 mg SC
(N = 410)
Any AE leading to treatment discontinuation 48 (12)
 Investigations 19 (5)
  Increased ALT 11 (3)
  Increased AST 5 (1)
  Increased hepatic enzyme 4 (<1)
 Skin and subcutaneous tissue disorders 12 (3)
  Allergic dermatitis 3 (<1)
 Gastrointestinal disorders 4 (<1)
  Colitis 3 (<1)
 Hepatobiliary disorders 4 (<1)
 Infections and infestations 4 (<1)
  1. AE Adverse event, ALT Alanine transaminase, AST Aspartate transaminase, SC Subcutaneous